NO971895L - Inhibitorer av apolipoprotein <beta>-syntesen - Google Patents

Inhibitorer av apolipoprotein <beta>-syntesen

Info

Publication number
NO971895L
NO971895L NO971895A NO971895A NO971895L NO 971895 L NO971895 L NO 971895L NO 971895 A NO971895 A NO 971895A NO 971895 A NO971895 A NO 971895A NO 971895 L NO971895 L NO 971895L
Authority
NO
Norway
Prior art keywords
apolipoprotein
inhibitors
beta
synthesis
Prior art date
Application number
NO971895A
Other languages
English (en)
Other versions
NO971895D0 (no
NO311937B1 (no
Inventor
Jan Heeres
Leo Jacobus Jozef Backx
Robert Jozef Maria Hendrickx
Luc Alfons Leo Van Der Eycken
Didier Robert Guy G Courcelles
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/455,304 external-priority patent/US5521186A/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO971895D0 publication Critical patent/NO971895D0/no
Publication of NO971895L publication Critical patent/NO971895L/no
Publication of NO311937B1 publication Critical patent/NO311937B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19971895A 1994-10-27 1997-04-24 Inhibitorer av apolipoprotein <beta>-syntesen NO311937B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94203120 1994-10-27
US08/455,304 US5521186A (en) 1994-10-27 1995-05-31 Apolipoprotein-β synthesis inhibitors
PCT/EP1995/004111 WO1996013499A1 (en) 1994-10-27 1995-10-19 Apolipoprotein-b synthesis inhibitors

Publications (3)

Publication Number Publication Date
NO971895D0 NO971895D0 (no) 1997-04-24
NO971895L true NO971895L (no) 1997-04-24
NO311937B1 NO311937B1 (no) 2002-02-18

Family

ID=26136684

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19971895A NO311937B1 (no) 1994-10-27 1997-04-24 Inhibitorer av apolipoprotein <beta>-syntesen

Country Status (30)

Country Link
US (1) US5929075A (no)
EP (1) EP0788496B1 (no)
JP (1) JP3025907B2 (no)
KR (1) KR100227231B1 (no)
CN (1) CN1068000C (no)
AP (1) AP779A (no)
AT (1) ATE198889T1 (no)
AU (1) AU697744C (no)
BG (1) BG63694B1 (no)
BR (1) BR9509436A (no)
CA (1) CA2203274C (no)
CY (1) CY2256B1 (no)
CZ (1) CZ286476B6 (no)
DE (3) DE122007000005I2 (no)
DK (1) DK0788496T3 (no)
ES (1) ES2155535T3 (no)
FI (1) FI119548B (no)
GR (1) GR3035519T3 (no)
HR (1) HRP950532B1 (no)
HU (1) HU219862B (no)
IL (1) IL115771A (no)
LU (1) LU91306I2 (no)
NO (1) NO311937B1 (no)
NZ (1) NZ295353A (no)
OA (1) OA10479A (no)
PT (1) PT788496E (no)
RO (1) RO118715B1 (no)
SK (1) SK281908B6 (no)
TR (1) TR199501295A2 (no)
WO (1) WO1996013499A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001521899A (ja) * 1997-11-03 2001-11-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 脂質低下剤組成物
AU3710099A (en) * 1998-04-27 1999-11-16 Janssen Pharmaceutica N.V. Pellets having a core coated with a lipid lowering agent and a polymer
EP1140917B1 (en) * 1998-12-22 2003-03-26 Janssen Pharmaceutica N.V. S-oxide lipid lowering compounds
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US20050132022A1 (en) * 2003-12-12 2005-06-16 International Business Machines Corporation Computer system with LAN-based I/O
JP4994043B2 (ja) * 2004-01-21 2012-08-08 エランコ・アニマル・ヘルス・アイルランド・リミテッド ミトラタピデ経口用溶液
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
EP1737460A2 (en) * 2004-04-09 2007-01-03 Janssen Pharmaceutica N.V. Intermittent dosing regimen for the treatment of overweight with mtp-inhibitors
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
WO2007015162A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
MEP6808A (xx) * 2006-02-23 2010-02-10 Lundbeck & Co As H Priperidinoilpirodolini agonisti receptora menalokortina tipa 4
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
CN101583593A (zh) 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
EP2152698B1 (en) 2007-05-25 2010-07-21 Janssen Pharmaceutica, N.V. Improved synthesis of (2s-cis)-2-(bromomethyl)-2-(4-chlorophenyl)-1,3 dioxolane-4-methanol methanesulfonate(ester)
ES2421920T3 (es) * 2008-08-06 2013-09-06 Pfizer Ltd Compuestos de diazepina y diazocano como agonistas de MC4
WO2011144653A1 (en) * 2010-05-19 2011-11-24 Sandoz Ag Process for the preparation of chiral triazolones
SI3762368T1 (sl) 2018-03-08 2022-06-30 Incyte Corporation Aminopirazin diolne spojine kot zaviralci PI3K-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4313953A (en) * 1978-06-23 1982-02-02 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4619931A (en) * 1983-02-28 1986-10-28 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles
CA1292472C (en) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
NZ223799A (en) * 1987-03-25 1989-12-21 Janssen Pharmaceutica Nv Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions
CA1331757C (en) * 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
AU6359594A (en) * 1993-03-04 1994-09-26 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors

Also Published As

Publication number Publication date
EP0788496A1 (en) 1997-08-13
WO1996013499A1 (en) 1996-05-09
SK281908B6 (sk) 2001-09-11
ATE198889T1 (de) 2001-02-15
DE122007000005I2 (de) 2008-04-24
CY2256B1 (en) 2003-07-04
SK50797A3 (en) 1998-04-08
HRP950532B1 (en) 2001-06-30
AP779A (en) 1999-11-03
NO971895D0 (no) 1997-04-24
MX9703074A (es) 1997-07-31
CZ119897A3 (cs) 1998-03-18
RO118715B1 (ro) 2003-09-30
CA2203274C (en) 2002-02-19
EP0788496B1 (en) 2001-01-24
DE69519995D1 (en) 2001-03-01
FI119548B (fi) 2008-12-31
FI971784A0 (fi) 1997-04-25
PT788496E (pt) 2001-07-31
DK0788496T3 (da) 2001-06-18
US5929075A (en) 1999-07-27
GR3035519T3 (en) 2001-06-29
TR199501295A2 (tr) 1996-06-21
AU697744B2 (en) 1998-10-15
IL115771A (en) 2000-02-29
CN1161695A (zh) 1997-10-08
AP9700968A0 (en) 1997-04-30
OA10479A (en) 2002-04-09
JP3025907B2 (ja) 2000-03-27
BG63694B1 (bg) 2002-09-30
HRP950532A2 (en) 1997-08-31
HUT77360A (hu) 1998-03-30
NZ295353A (en) 1998-08-26
LU91306I2 (fr) 2007-03-19
IL115771A0 (en) 1996-01-19
AU697744C (en) 2002-08-22
CN1068000C (zh) 2001-07-04
KR100227231B1 (ko) 1999-11-01
FI971784A (fi) 1997-04-25
JPH09511759A (ja) 1997-11-25
NO311937B1 (no) 2002-02-18
HU219862B (hu) 2001-08-28
DE69519995T2 (de) 2001-08-23
ES2155535T3 (es) 2001-05-16
DE122007000005I1 (de) 2007-04-26
AU3868095A (en) 1996-05-23
CZ286476B6 (en) 2000-04-12
BG101402A (en) 1997-10-31
BR9509436A (pt) 1998-01-06
CA2203274A1 (en) 1996-05-09

Similar Documents

Publication Publication Date Title
NO971895D0 (no) Inhibitorer av apolipoprotein &lt;beta&gt;-syntesen
LV11178A (lv) 3-Ú4-(2-aminoetoksi) benzoil¾-2-aril-6-hidroksibenzoÚb¾tiofenu sintezes panemiens
FI980033A0 (fi) Solujen kiinnittymisen inhibiittoreita
DE69608448D1 (de) Reduktion des biobewuchses
NO970153L (no) Fremgangsmåte for syntese av substituerte sulfoksider
ID24638A (id) Senyawa-senyawa anti aritmia bispidina
EE04241B1 (et) Apolipoproteiin-B sünteesi inhibiitorid
NO982716D0 (no) FremgangsmÕte og blandinger for syntese av dioksalan-nukleotider med &lt;beta&gt;-konfigurasjon
NO20011083L (no) Krystallinske former av EtOC2--CH2-(R)Cgl-Aze-Pab-OH
FI931408A (fi) Anordning foer fraesning av amorfiska staolremsor
FI973591A0 (fi) Nya syntetiserade kryptofysiner
NO940912D0 (no) Rensing av kuldemedium
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
BR9508380A (pt) Derivados de azalonas heterocíclicos anti-helicobacter
NO990832D0 (no) Syntese av bisendolylmalimider
NO963187D0 (no) Fremgangsmåte for syntese av gamma-pyroner
DE69433141D1 (de) Zusammensetzungen aus kohleteerschlamm
NO940190L (no) Anvendelse av alpha-ketoglutarat
FI970828A0 (fi) Spirostanyyliglykosidien kiteitä
NO952949D0 (no) Forlöpere av anti-inflamatoriske 3-acyl-2-oksindol-1-karboksamider
FI942576A0 (fi) Behandling av plasma
NO953630D0 (no) Anvendelse av blandinger inneholdende acetaler
NO980501D0 (no) Fôring av rör
KR950024188U (ko) 갈치주낚용 도래의 고정구
IS4339A (is) Hömlun ljóssundurliðunar á 3-setnum-2-oxindólum

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA

MM1K Lapsed by not paying the annual fees